Trans-Pacific Partnership agreed, but national ratifications still required

5 October 2015
2019_biotech_test_vial_discovery_big

The USA and 11 other Pacific Rim nations on Monday agreed to the Trans-Pacific Partnership, the largest regional trade accord in history, a potentially precedent-setting model for global commerce and worker standards that would tie together 40% of the world’s economy.

The TPP eliminates or reduces tariff and non-tariff barriers across substantially all trade in goods and services and covers the full spectrum of trade, including goods and services trade and investment, so as to create new opportunities and benefits for our businesses, workers, and consumers.

The TPP still faces months of debate in Congress and will inject a new flash point into both parties’ presidential contests. The list of countries the TPP would include: Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, the USA, Singapore and Vietnam.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...





Today's issue

Company Spotlight





More Features in Biotechnology